Moderna’s shares rose as much as 18% on Wednesday after the company announced that an early test of the coronavirus vaccine produced antibodies in all participants. A dose range induced immune responses in all 45 patients in the phase 1 trial and was “generally safe and well tolerated,” Moderna said …
Read More »Moderna fires 18% after early test of coronavirus vaccine produces antibodies in all patients
